Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Nov. 9 — Boehringer Ingelheim GmbH moved closer to completing its proposed $25 billion asset swap with Sanofi after unloading vaccine and drug assets to rival Ceva Sante Animale SA.
The European Commission signed off on the deal Nov. 9, conditioned on the sale of a number of drugs and related production technology. The deal still requires approval from other antitrust regulators, including the Federal Trade Commission.
The EU commission’s investigation into Boehringer’s purchase of Sanofi’s animal health division, Merial, found potential competition problems in several vaccines and anti-inflammatory drugs. It accepted the companies’ offer to divest a number of Merial’s products, including vaccines Circovac, Progressis, Parvovax, Parvovurax and Mucossifa and pharmaceuticals Ketofen, Wellicox, Allevinix, Genixine, Equioxx Injectable and Equioxx Paste.
The proposed sale to Ceva will require a separate merger approval, but faces fewer hurdles. The commission’s statement on the proposed divestitures called Ceva “a suitable purchaser with strong capabilities and incentives to run the divested businesses successfully in the long term.”
Boehringer announced in June that it would purchase Sanofi’s animal health unit in exchange for its consumer health division. The EU cleared the other side of the swap, Sanofi’s acquisition of Boehringer’s consumer health business, in August.
“This is another important step towards the closing of the overall BI/Sanofi business swap,” Sanofi said in a statement. The parties still expect to close the transaction by year-end 2016, Sanofi said.
To contact the reporter on this story: Eleanor Tyler in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Tiffany Friesen Milone at email@example.com
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)